Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	2.12B
Revenue (ttm)	4.72M
Net Income (ttm)	-199.42M
Shares Out	66.80M
EPS (ttm)	-3.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	965,858
Open	32.04
Previous Close	32.03
Day's Range	31.35 - 32.94
52-Week Range	15.23 - 32.93
Beta	0.56
Analysts	Buy
Price Target	44.38 (+39.6%)
Earnings Date	Nov 7, 2023

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN0477...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2018
• Employees: 210
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX

Financial Performance

In 2022, CRNX's revenue was $4.74 million, an increase of 339.42% compared to the previous year's $1.08 million. Losses were -$163.92 million, 52.3% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is $44.38, which is an increase of 39.60% from the latest price.

Price Target

$44.38

(39.60% upside)

Analyst Consensus: Buy